Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Assets: 2019-2024

Historic Assets for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $615.9 million.

  • Keros Therapeutics' Assets rose 28.23% to $742.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $742.8 million, marking a year-over-year increase of 28.23%. This contributed to the annual value of $615.9 million for FY2024, which is 66.44% up from last year.
  • Latest data reveals that Keros Therapeutics reported Assets of $615.9 million as of FY2024, which was up 66.44% from $370.0 million recorded in FY2023.
  • Over the past 5 years, Keros Therapeutics' Assets peaked at $615.9 million during FY2024, and registered a low of $255.3 million during FY2021.
  • Moreover, its 3-year median value for Assets was $370.0 million (2023), whereas its average is $430.9 million.
  • Its Assets has fluctuated over the past 5 years, first soared by 2,359.54% in 2020, then dropped by 5.27% in 2021.
  • Keros Therapeutics' Assets (Yearly) stood at $269.4 million in 2020, then fell by 5.27% to $255.3 million in 2021, then increased by 20.19% to $306.8 million in 2022, then rose by 20.62% to $370.0 million in 2023, then skyrocketed by 66.44% to $615.9 million in 2024.